Testing Pembrolizumab as Additional Therapy for Triple-Negative Breast Cancer

Program Overview

This clinical trial is investigating the effectiveness of pembrolizumab, an immunotherapy drug, in treating patients with triple-negative breast cancer. Pembrolizumab may help the immune system attack cancer cells and prevent them from growing and spreading. The study will compare patients who receive pembrolizumab after chemotherapy to those who do not, to see if it improves disease-free survival and overall survival.

Description

The main goal of this study is to see if pembrolizumab can help patients with triple-negative breast cancer live longer without the cancer coming back. Patients who have at least 1 cm of cancer left after chemotherapy or have cancer in their lymph nodes are eligible. The study will also look at how pembrolizumab affects overall survival and the time until cancer spreads to other parts of the body.

Participants will be randomly assigned to one of two groups. One group will receive pembrolizumab through an IV every 42 days for a year, while the other group will be monitored without additional treatment. All participants may receive radiation therapy and will have regular follow-ups for up to 10 years.

The study will also collect blood and tissue samples for future research. Patients will be monitored for side effects and how well they tolerate the treatment. The study will also explore how pembrolizumab affects quality of life and long-term health outcomes.

Eligibility Criteria

Locations